A study compared the performance of different models using routinely collected clinicopathological data from women with HR-positive/HER2-negative breast cancer
Integrating DNA and RNA profiling is a promising approach to advance cancer characterisation and guide clinical decision-making
ESMO plays a central role in developing long-lasting recommendations for a safe and effective use of artificial intelligence supporting oncology stakeholders
AI-driven approaches can help to design minibinders, which may bring new T-cell receptor-based therapies closer to the clinic
Tumour reduction was observed with IMA203CD8 across different PRAME-expressing cancers in a phase I trial
Benefits were seen across most predefined subgroups investigated in the practice-changing POD1UM-303/InterAACT-2 study
Encouraging data were reported for SHR-1701 added to first-line CAPOX in a post-hoc analysis of patients with high-risk features from a Chinese study
Integrating spatial profiling, single-cell technologies and blood-based correlates may help reveal why immunotherapy is effective in some tumours but not others
2025 ESMO Immuno-Oncology Awardee, Ignacio Melero, is confident that combinations and novel multispecific agents will result in synergistic strategies to ensure the continued success of cancer immunotherapy
Phase I–II studies showcase the clinical potential of novel ADCs with enhanced targeting and/or payload strategies
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.